Early detection is a top priority in the field of Alzheimer’s research, and one indicator of Alzheimer’s disease is the buildup of tau in the brain. What is tau, though? How can we detect this protein, and what can it tell us about a person’s symptoms or disease progression? Dr. Gil Rabinovici, a leader in the field of brain imaging, joins Dementia Matters this week for an in-depth discussion on the role of tau PET scans in Alzheimer’s disease detection, research and clinical care.
Guest: Gil Rabinovici, MD, professor, Department of Neurology, University of California San Francisco (UCSF), director, UCSF Alzheimer’s Disease Research Center, study chair, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies, co-principal investigator, Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS)
Show Notes
Are you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 4/7/2026. After this date, you will no longer be able to access the course or claim credit.
Read “Criteria for Diagnosis and Staging of Alzheimer’s Disease,” mentioned by Dr. Rabinovici at 18:43, on the Alzheimer’s Association’s website:
Listen to our past episode with Dr. David Wolk, “LATE, Explained,” mentioned by Dr. Rabinovici at 26:31 on Spotify , Apple Podcasts and on our website:
Connect with us
Find transcripts and more at our website:
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter:
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter:
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production:
source